SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-287687
Filing Date
2022-11-17
Accepted
2022-11-17 16:23:57
Documents
18
Period of Report
2022-11-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d383621d8k.htm   iXBRL 8-K 36480
2 EX-1.1 d383621dex11.htm EX-1.1 189564
3 EX-4.1 d383621dex41.htm EX-4.1 57504
4 EX-5.1 d383621dex51.htm EX-5.1 12222
5 EX-99.1 d383621dex991.htm EX-99.1 7368
9 GRAPHIC g383621g1117001543665.jpg GRAPHIC 1414
10 GRAPHIC g383621g1117002123369.jpg GRAPHIC 3252
  Complete submission text file 0001193125-22-287687.txt   515374

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA tnya-20221116.xsd EX-101.SCH 2884
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE tnya-20221116_lab.xml EX-101.LAB 18738
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tnya-20221116_pre.xml EX-101.PRE 11730
12 EXTRACTED XBRL INSTANCE DOCUMENT d383621d8k_htm.xml XML 3490
Mailing Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080 415-865-2066
Tenaya Therapeutics, Inc. (Filer) CIK: 0001858848 (see all company filings)

IRS No.: 813789973 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40656 | Film No.: 221398699
SIC: 2836 Biological Products, (No Diagnostic Substances)